Hepatitis C Virus NS3 Helicase Inhibitor Discovery
- PMID: 23762946
- Bookshelf ID: NBK143540
Hepatitis C Virus NS3 Helicase Inhibitor Discovery
Excerpt
The Hepatitis C virus (HCV) is a major cause of liver failure and hepatocellular carcinoma, with about 170 million people infected worldwide. Replication of HCV in human cells requires the action of the HCV non-structural protein 3 (NS3), which exhibits both protease and helicase activities. Since there are numerous NS3 protease inhibitors but few NS3 helicase inhibitors, the goal here was to develop specific NS3 helicase inhibitors. During assay development, we discovered that trace components in the dye mixtures thioflavine S and primuline were potent inhibitors of the NS3 helicase. Based on the common structure of these components we designed ML283. The probe candidate is a potent inhibitor of the NS3 helicase enzyme and can be synthesized in the necessary quantities for further investigation. ML283 is more potent and specific than other recently reported NS3 helicase inhibitors under the same assay conditions, allowing a direct comparison. Preliminary experiments indicate that this compound is able to penetrate cells and inhibit HCV replication with no significant cytotoxicity. Thus the probe would be a useful tool for the investigation of viral helicases.
Sections
- Resulting Publications
- Probe Structure & Characteristics
- Recommendations for Scientific Use of the Probe
- 1. Introduction
- 2. Materials and Methods
- 3. Results
- 4. Discussion
- Acknowledgments
- 5. References
- Appendix A. Details for the Material and Methods for the assays listed in Table 3
- Appendix B. NMR Data and LCMS Data for Probe Compound for Probe CID 50930730/ML283
- Appendix C. Continuation of Section 2.3, Probe Preparation
- Appendix D. Description of the outcome for the screen of 827 compounds from the NCI DTP compound collection
- Appendix E. Results of SciFinder substructure searches for the ML283 chemotype
References
Resulting Publications
-
- Mukherjee S, Hanson AM, Shadrick WR, Ndjomou J, Sweeney NL, Hernandez J, Bartczak D, Li K, Frankowski KJ, Heck JA, Arnold LA, Schoenen FJ, Frick DN. Identification and Analysis of Hepatitis C Virus NS3 Helicase Inhibitors Using Nucleic Acid Binding Assays. Nucleic Acids Res. 2012;40(17):8607–8621. - PMC - PubMed
-
- Ndjomou J, Kolli R, Mukherjee S, Shadrick WR, Hanson AM, Sweeney NL, Bartczak D, Li K, Frankowski KJ, Schoenen FJ, Frick DN. Fluorescent Primuline Derivatives Inhibit Hepatitis C Virus NS3-Catalyzed RNA Unwinding, Peptide Hydrolysis and Viral Replicase Formation. Antiviral Res. 2012;96(2):245–255. - PMC - PubMed
References
-
- Garber K. Hepatitis C: move over interferon. Nat Biotechnol. 2011;29:963–966. - PubMed
-
- Lindenbach BD, Rice CM. Unravelling hepatitis C virus replication from genome to function. Nature. 2005;436:933–938. - PubMed
-
- Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, Focaccia R, Younossi Z, Foster GR, Horban A, et al. Telaprevir for retreatment of HCV infection. N Engl J Med. 2011;364:2417–2428. - PubMed
Full SciFinder bibliography
-
- Cichero E, Basile A, Turco MC, Mazzei M, Fossa P. Scouting new molecular targets for CFTR therapy: the HSC70/BAG-1 complex. A computational study. Med. Chem. Res. 2012 doi: 10.1007/s00044-012-9985-1. - DOI
-
- Isono T, Omura N. Copper electroplating bath compositions and method for filling via holes and through holes by electroplating of copper. JP 2012021202 A 20120202 Jpn. Kokai Tokkyo Koho. 2012
-
- Md.Sheikh RK, Farouqui AN, Yahya R, Hassan A. Effect of acid modification on dyeing properties of Rajshahi silk fabric with different dye classes. Fibers and Polymers. 2011;12:642–647.
-
- Hariharasuthan R, Nageswara RA. Comparative studies of Sorel’s cement on selected dyes. Indian Journal of Science and Technology. 2011;4:410–413.
Publication types
LinkOut - more resources
Full Text Sources